384 related articles for article (PubMed ID: 26840338)
21. Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study.
Ilany J; Bhandari H; Nabriski D; Toledano Y; Konvalina N; Cohen O
Diabetes Obes Metab; 2018 May; 20(5):1186-1192. PubMed ID: 29316176
[TBL] [Abstract][Full Text] [Related]
22. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
23. Comparative effectiveness and safety of different basal insulins in a real-world setting.
Ji L; Zhang P; Zhu D; Lu J; Guo X; Wu Y; Li X; Ji J; Jia W; Yang W; Zou D; Zhou Z; Gao Y; Garg SK; Pan C; Weng J; Paul SK;
Diabetes Obes Metab; 2017 Aug; 19(8):1116-1126. PubMed ID: 28230322
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Switching from Insulin Glargine 100 U/mL to the Same Dose of Glargine 300 U/mL in Japanese Type 1 and 2 Diabetes Patients: A Retrospective Analysis.
Nakanishi S; Iwamoto M; Kamei S; Hirukawa H; Shimoda M; Tatsumi F; Kohara K; Obata A; Kimura T; Kinoshita T; Irie S; Sanada J; Fushimi Y; Nishioka M; Mizoguchi A; Kameyama M; Mune T; Kaku K; Kaneto H
Intern Med; 2018; 57(10):1381-1389. PubMed ID: 29760318
[TBL] [Abstract][Full Text] [Related]
26. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of glycemic control in type 1 diabetic patients switched from basal insulin glargine 100 U/ml to glargine 300 U/ml in real life.
Oriot P; Jérémie W; Buysschaert M
Expert Rev Endocrinol Metab; 2018 May; 13(3):167-171. PubMed ID: 30058899
[TBL] [Abstract][Full Text] [Related]
28. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.
Ritzel R; Roussel R; Bolli GB; Vinet L; Brulle-Wohlhueter C; Glezer S; Yki-Järvinen H
Diabetes Obes Metab; 2015 Sep; 17(9):859-67. PubMed ID: 25929311
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial.
Danne T; Tamborlane WV; Malievsky OA; Franco DR; Kawamura T; Demissie M; Niemoeller E; Goyeau H; Wardecki M; Battelino T
Diabetes Care; 2020 Jul; 43(7):1512-1519. PubMed ID: 32430458
[TBL] [Abstract][Full Text] [Related]
30. Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies.
Ji L; Bi Y; Ye S; Huang Y; Zhang X; Shang S; Cui N; Yin H; Zhang M
Diabetes Res Clin Pract; 2021 Jun; 176():108848. PubMed ID: 33945841
[TBL] [Abstract][Full Text] [Related]
31. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Lingvay I; Pérez Manghi F; García-Hernández P; Norwood P; Lehmann L; Tarp-Johansen MJ; Buse JB;
JAMA; 2016 Mar; 315(9):898-907. PubMed ID: 26934259
[TBL] [Abstract][Full Text] [Related]
32. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
PLoS One; 2018; 13(1):e0190579. PubMed ID: 29370218
[TBL] [Abstract][Full Text] [Related]
33. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Hollander PA; Carofano WL; Lam RLH; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rendell MS; Home PD; Gallwitz B; Rosenstock J
Diabetes Obes Metab; 2018 Sep; 20(9):2229-2237. PubMed ID: 29761615
[TBL] [Abstract][Full Text] [Related]
35. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
Owens DR; Traylor L; Mullins P; Landgraf W
Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
[TBL] [Abstract][Full Text] [Related]
36. Real-world Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Mellitus During the Period of Ramadan in Four Countries (Egypt, Jordan, Lebanon, and Turkey): A Prospective Observational Study.
Hassanein M; Shaltout I; Malek R; Assaad Khalil S; Ballout H; Annabi F; Shereen M
Curr Diabetes Rev; 2024; 20(5):e110823219694. PubMed ID: 37581325
[TBL] [Abstract][Full Text] [Related]
37. Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes.
Ritzel R; Roussel R; Giaccari A; Vora J; Brulle-Wohlhueter C; Yki-Järvinen H
Diabetes Obes Metab; 2018 Mar; 20(3):541-548. PubMed ID: 28862801
[TBL] [Abstract][Full Text] [Related]
38. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study.
Ritzel R; Harris SB; Baron H; Florez H; Roussel R; Espinasse M; Muehlen-Bartmer I; Zhang N; Bertolini M; Brulle-Wohlhueter C; Munshi M; Bolli GB
Diabetes Care; 2018 Aug; 41(8):1672-1680. PubMed ID: 29895556
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
